Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Tassi who wrote (50254)	1/20/2000 12:08:00 PM
From: Anthony@Pacific	Read Replies (9) \| Respond to of 122087

AVAN<---a little Biotech with BiG Money backers and UNDISCOVERED ..trading at 4 3/16 I own it at 4 and at 3 3/4 and believe it is dirt cheap ...I think it will go... News a feew days ago..I wont mention this one again..either you are in or not.. NEEDHAM, Mass. (Dow Jones)--Avant Immunotherapeutics Inc. (AVAN) received a $6 million payment from Novartis Pharma AG (Z.NOV) in connection with the license of a product that reduces immune-system rejections of transplanted organs. In a press release Thursday, Avant said it agreed on an option to license the product, TP10, in 1997. The license agreement provides for an additional $14 million in milestone payments, as well as royalties on product sales. Avant develops products that use the human immune response to prevent and treat disease. -Jason Overdorf; Dow Jones Newswires; 201-938-5388